Literature DB >> 18327550

Expression, purification, and in vivo administration of a promising anti-idiotypic HIV-1 vaccine.

Johannes Simon Gach1, Heribert Quendler, Boris Ferko, Hermann Katinger, Renate Kunert.   

Abstract

To date only a few neutralizing antibodies against HIV-1 exist. Since these neutralizing antibodies are only rarely found in sera of HIV-1 infected individuals an active vaccine is required. We recently developed murine anti-idiotypic antibody Ab2/3H6 against monoclonal antibody (mAb) 2F5, which is one of the most prominent neutralizing antibodies. Anti-idiotypic antibody Ab2/3H6 has been partially humanized and expressed as whole immunoglobulin G in Chinese hamster ovary cells in order to minimize the human anti-mouse antibody response. Here we describe the expression, purification, and immunohistochemical characterization of the chimeric Ab2/3H6 Fab fragment, which was finally used beside the whole IgG1 as an antigen for immunization of guinea pigs. The crude sera were screened for specific antibodies against the epitope of mAb 2F5 ELDKWA as well as for reactivity against HIV-1 gp41.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18327550     DOI: 10.1007/s12033-008-9054-7

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  15 in total

1.  HIV vaccine design and the neutralizing antibody problem.

Authors:  Dennis R Burton; Ronald C Desrosiers; Robert W Doms; Wayne C Koff; Peter D Kwong; John P Moore; Gary J Nabel; Joseph Sodroski; Ian A Wilson; Richard T Wyatt
Journal:  Nat Immunol       Date:  2004-03       Impact factor: 25.606

2.  Structural analysis and in vivo administration of an anti-idiotypic antibody against mAb 2F5.

Authors:  Johannes S Gach; Heribert Quendler; Stefanie Strobach; Hermann Katinger; Renate Kunert
Journal:  Mol Immunol       Date:  2007-09-04       Impact factor: 4.407

3.  Inhibition of HIV-1 infection in vitro by monoclonal antibodies to the complement receptor type 3 (CR3): an accessory role for CR3 during virus entry?

Authors:  H Stoiber; I Frank; M Spruth; M Schwendinger; B Mullauer; J M Windisch; R Schneider; H Katinger; I Ando; M P Dierich
Journal:  Mol Immunol       Date:  1997 Aug-Sep       Impact factor: 4.407

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Stable recombinant expression of the anti HIV-1 monoclonal antibody 2F5 after IgG3/IgG1 subclass switch in CHO cells.

Authors:  R Kunert; W Steinfellner; M Purtscher; A Assadian; H Katinger
Journal:  Biotechnol Bioeng       Date:  2000-01-05       Impact factor: 4.530

6.  Direct measurement of antibody affinity distribution by hapten-inhibition enzyme immunoassay.

Authors:  A Nieto; A Gaya; M Jansa; C Moreno; J Vives
Journal:  Mol Immunol       Date:  1984-06       Impact factor: 4.407

7.  Anti-idiotypic antibody Ab2/3H6 mimics the epitope of the neutralizing anti-HIV-1 monoclonal antibody 2F5.

Authors:  Renate E Kunert; Robert Weik; Boris Ferko; Gabriela Stiegler; Hermann Katinger
Journal:  AIDS       Date:  2002-03-08       Impact factor: 4.177

8.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.

Authors:  T Muster; F Steindl; M Purtscher; A Trkola; A Klima; G Himmler; F Rüker; H Katinger
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

9.  Sensitive silver staining of protein in sodium dodecyl sulfate-polyacrylamide gels using an azo dye, calconcarboxylic acid, as a silver-ion sensitizer.

Authors:  Li-Tai Jin; Sun-Young Hwang; Gyurng-Soo Yoo; Jung-Kap Choi
Journal:  Electrophoresis       Date:  2004-08       Impact factor: 3.535

10.  A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1.

Authors:  M Purtscher; A Trkola; G Gruber; A Buchacher; R Predl; F Steindl; C Tauer; R Berger; N Barrett; A Jungbauer
Journal:  AIDS Res Hum Retroviruses       Date:  1994-12       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.